During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Patients with early-stage melanoma who experience relapse following wide local excision face worse survival outcomes.

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...